Influence of CYP2C8*2 on the pharmacokinetics of pioglitazone in healthy African-American volunteers.

ABSTRACT:

Study objectives

To determine the influence of the Cytochrome P450 (CYP) 2C8*2 polymorphism on pioglitazone pharmacokinetics in healthy African-American volunteers.

Design

Prospective, open-label, single-dose pharmacokinetic study.

Setting

University of Colorado Hospital Clinical and Translational Research Center.

Participants

Healthy African-American volunteers between 21 and 60 years of age were enrolled in the study based on CYP2C8 genotype: CYP2C8*1/*1 (9 participants), CYP2C8*1/*2 (7 participants), and CYP2C8*2/*2 (1 participant).

Intervention

Participants received a single 15-mg dose of pioglitazone in the fasted state, followed by a 48-hour pharmacokinetic study.

Measurements and main results

Plasma concentrations of pioglitazone and its M-

SUBMITTER: Aquilante CL 

PROVIDER: S-EPMC3760990 | biostudies-literature | 2013 Sep

REPOSITORIES: biostudies-literature